Morphosys AG Says 2024 Financial Guidance Published On January 30, 2024, Cannot Be Maintained And Therefore Was Revoked
April 29 (Reuters) -MorphoSys AG MORG.DE:
MORPHOSYS' 2024 FINANCIAL GUIDANCE PUBLISHED ON JANUARY 30, 2024, CANNOT BE MAINTAINED AND THEREFORE WAS REVOKED
WILL NO LONGER MAKE A FORECAST FOR GROSS MARGIN OR REVENUES FROM MONJUVI PRODUCT SALES
COST OF SALES IN Q1 OF 2024 AMOUNTED TO EUR 2.8 MILLION (3M 2023: EUR 1.0 MILLION)
FOR 2024, MORPHOSYS EXPECTS RESEARCH AND DEVELOPMENT EXPENSES OF EUR 170 MILLION TO EUR 185 MILLION ON A STANDALONE BASIS
SHAREHOLDER ACCEPTANCE PERIOD FOR NOVARTIS OFFER HAS COMMENCED AND WILL END ON MAY 13, 2024, AT 24:00 HOURS CEST
Q1 MONJUVI (TAFASITAMAB-CXIX) U.S. NET PRODUCT SALES OF US$ 6.4 MILLION
PLANS SUBMIT A NEW DRUG APPLICATION FOR PELABRESIB IN COMBINATION WITH RUXOLITINIB IN MYELOFIBROSIS TO US FDA IN SECOND HALF OF 2024
MORPHOSYS - PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION FOR PELABRESIB IN COMBINATION WITH RUXOLITINIB IN MYELOFIBROSIS TO EMA IN H2 2024
FOR Q1 2024, CONSOLIDATED NET LOSS WAS EUR 311.0 MILLION (Q1 2023: CONSOLIDATED NET LOSS OF EUR 32.2 MILLION)
Source text for Eikon: ID:nBw1S3zz9a
Further company coverage: MORG.DE
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
